Diabetes News and Research

Latest Diabetes News and Research

Drugmakers' business practices draw scrutiny

Three top California Medicaid officials in charge of pharmacy issues failed to disclose trips paid for by drug-industry funded business groups, California Watch/San Francisco Chronicle reports. Officials who are directly involved in setting drug policy and negotiating payments took about 12 trips paid for by these nonprofit business groups. The nonprofits hold conferences such as the those attended by the Medicaid officials and raise their money through fees from drug representatives who attend conferences, too.

1 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Biodel seeks FDA marketing approval for VIAject

Biodel Inc. announced today that the U.S. Food and Drug Administration has accepted for review the company’s new drug application (NDA) seeking approval to market VIAject® for the treatment of diabetes. VIAject® is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs.

1 Mar 2010

FDA accepts for filing VIVUS' Qnexa NDA

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for its investigational drug, Qnexa®, for the treatment of obesity. The target date for the FDA to complete its review of the Qnexa NDA is October 28, 2010.

1 Mar 2010

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.

1 Mar 2010

Determining personal risk for genetic disorders essential

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.

1 Mar 2010

Habits of modern life may shorten life-span of the Millennium Generation

All parents dream of a better life for their children, but because of the habits of modern life, the Millennium Generation may be the first to suffer a shorter life-span.

1 Mar 2010

Government has yet to confirm funding for ADI

With the sunset date for the Aboriginal Diabetes Initiative (ADI) rapidly approaching, the government has yet to confirm whether or not funding will continue after March 31st.

1 Mar 2010

Using genetic engineering techniques in pigs, scientists create new model of diabetes

The incidence of diabetes is rising worldwide. Using genetic engineering techniques in pigs, scientists at Ludwig-Maximilians-Universität in Munich have created a new model of this metabolic disorder, which recapitulates many features of the disease, and promises to contribute significantly to improvements in diagnosis and therapy.

1 Mar 2010

Inadequate sleep may lead to increase in belly fat

A study in the March 1 issue of the journal SLEEP shows that African-American and Hispanic young adults with short or long sleep durations had greater increases in belly fat over a five-year period compared with those who reported sleeping six to seven hours a night.

1 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial

Efforts to prevent childhood obesity should begin far earlier than currently thought-perhaps even before birth-especially for minority children, according to a new study that tracked 1,826 women from pregnancy through their children's first five years of life.

1 Mar 2010

Study associates frequent napping with elevated prevalence of type 2 diabetes in older Chinese population

A study in the March 1 issue of the journal Sleep shows that frequent napping is associated with an elevated prevalence of type 2 diabetes and impaired fasting glucose in an older Chinese population.

1 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Body repairs itself through microvesicles: New hope for tissue regeneration

Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.

27 Feb 2010

Cotton thread as core material in 'lab-on-chip' devices to detect kidney failure and diabetes

A discovery by Monash University scientists could see humble cotton thread emerge as a core material in low-cost 'lab-on-chip' devices capable of detecting diseases such as kidney failure and diabetes.

27 Feb 2010

Of the 2.3M inmates, only 1.5M meet DSM IV medical criteria for substance abuse: CASA

Of the 2.3 million inmates crowding our nation's prisons and jails, 1.5 million meet the DSM IV medical criteria for substance abuse or addiction, and another 458,000, while not meeting the strict DSM IV criteria, had histories of substance abuse; were under the influence of alcohol or other drugs at the time of their crime; committed their offense to get money to buy drugs; were incarcerated for an alcohol or drug law violation; or shared some combination of these characteristics, according to Behind Bars II: Substance Abuse and America's Prison Population. Combined these two groups constitute 85 percent of the U.S. prison population.

27 Feb 2010

Blacks less likely to know they have atrial fibrillation or about use of warfarin

A large nationwide study that includes neurologists from Mayo Clinic has found that blacks are substantially less likely than whites to know that they have atrial fibrillation or to use warfarin, the most common treatment for the condition. Atrial fibrillation, an abnormal heart rhythm, significantly increases risk of stroke. Warfarin is known to reduce that risk.

27 Feb 2010

University of Michigan Health System opens new facility for eye care, diabetes research

On March 1, the first eye patients will enter an innovative new $132 million facility that expands the University of Michigan Health System's capacity for eye care, research and education, and unites diabetes researchers as they work to accelerate the search for a cure and prevention of diabetes.

27 Feb 2010

Diabetes News and Research

Latest Diabetes News and Research

Drugmakers' business practices draw scrutiny

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Biodel seeks FDA marketing approval for VIAject

FDA accepts for filing VIVUS' Qnexa NDA

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Determining personal risk for genetic disorders essential

Habits of modern life may shorten life-span of the Millennium Generation

Government has yet to confirm funding for ADI

Using genetic engineering techniques in pigs, scientists create new model of diabetes

Inadequate sleep may lead to increase in belly fat

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial

Study associates frequent napping with elevated prevalence of type 2 diabetes in older Chinese population

Precise immune disturbances leading to Coeliac disease: More insight

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Body repairs itself through microvesicles: New hope for tissue regeneration

Cotton thread as core material in 'lab-on-chip' devices to detect kidney failure and diabetes

Of the 2.3M inmates, only 1.5M meet DSM IV medical criteria for substance abuse: CASA

Blacks less likely to know they have atrial fibrillation or about use of warfarin

University of Michigan Health System opens new facility for eye care, diabetes research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Diabetes News and Research

Latest Diabetes News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in